Table 4. Correlations between expression of serine-metabolism–associated enzymes and clinicopathological characteristics.
| Parameters | PHGDH in tumor | PSAT1 in tumor | PSPH in tumor | PSPH in stroma | ||||||||
| Negative n = 452 (%) | Positive n = 257 (%) | P-value* | Negative n = 526 (%) | Positive n = 183 (%) | P-value* | Negative n = 611 (%) | Positive n = 98 (%) | P-value* | Negative n = 625 (%) | Positive n = 84 (%) | P-value* | |
| Age (yr, mean ±SD) | 49.6±10.5 | 49.7±11.6 | 7.656 | 49.6±10.7 | 49.8±11.6 | 6.504 | 49.7±10.8 | 49.7±11.7 | 7.896 | 49.8±10.9 | 48.9±10.7 | 4.112 |
| Histologic grade | <0.001 | 1.608 | <0.001 | 0.001 | ||||||||
| I/II | 353 (78.1) | 124 (48.2) | 361 (68.6) | 116 (63.4) | 437 (71.5) | 40 (40.8) | 434 (69.4) | 43 (51.2) | ||||
| III | 99 (21.9) | 133 (51.8) | 165 (31.4) | 67 (36.6) | 174 (28.5) | 58 (59.2) | 191 (30.6) | 41 (48.8) | ||||
| ER | <0.001 | 0.392 | <0.001 | <0.001 | ||||||||
| Negative | 81 (17.9) | 173 (67.3) | 177 (33.7) | 77 (42.1) | 179 (29.3) | 75 (76.5) | 204 (32.6) | 50 (59.5) | ||||
| Positive | 371 (82.1) | 84 (32.7) | 349 (66.3) | 106 (57.9) | 432 (70.7) | 23 (23.5) | 421 (67.4) | 34 (40.5) | ||||
| PR | <0.001 | 0.688 | <0.001 | <0.001 | ||||||||
| Negative | 150 (33.2) | 189 (73.5) | 241 (45.8) | 98 (53.6) | 258 (42.2) | 81 (82.7) | 283 (45.3) | 56 (66.7) | ||||
| Positive | 302 (66.8) | 68 (26.5) | 285 (54.2) | 85 (46.4) | 353 (57.8) | 17 (17.3) | 342 (54.7) | 28 (33.3) | ||||
| HER-2 | 6.784 | 0.360 | 5.568 | 0.120 | ||||||||
| Negative | 359 (79.4) | 202 (78.6) | 426 (81.0) | 135 (73.8) | 482 (78.9) | 79 (80.6) | 503 (80.5) | 58 (69.0) | ||||
| Positive | 93 (20.6) | 55 (21.4) | 100 (19.0) | 48 (26.2) | 129 (21.1) | 19 (19.4) | 122 (19.5) | 26 (31.0) | ||||
| Tumor stage | 0.408 | 0.160 | 1.232 | 0.048 | ||||||||
| T1 | 232 (51.3) | 112 (43.6) | 269 (51.1) | 75 (41.0) | 303 (49.6) | 41 (41.8) | 315 (50.4) | 29 (34.5) | ||||
| T2/T3 | 220 (48.7) | 145 (56.4) | 257 (48.9) | 108 (59.0) | 308 (50.4) | 57 (58.2) | 310 (49.6) | 55 (65.5) | ||||
| Nodal stage | 0.904 | 3.072 | 0.936 | 5.584 | ||||||||
| N0 | 257 (56.9) | 162 (63.0) | 316 (60.1) | 103 (56.3) | 354 (57.9) | 65 (66.3) | 371 (59.4) | 48 (57.1) | ||||
| N1/N2/N3 | 195 (43.1) | 95 (37.0) | 210 (39.9) | 80 (43.7) | 257 (42.1) | 33 (33.7) | 254 (40.6) | 36 (42.9) | ||||
| Ki-67 LI (%, mean ±SD) | 11.0±11.7 | 28.6±22.4 | <0.001 | 18.0±19.3 | 15.5±15.6 | 0.912 | 15.7±17.5 | 27.8±20.5 | <0.001 | 16.1±17.9 | 27.3±19.3 | <0.001 |
| Tumor recurrence | 2.184 | 2.328 | 0.808 | 1.192 | ||||||||
| Absent | 416 (92.0) | 230 (89.5) | 483 (91.8) | 163 (89.1) | 561 (91.8) | 85 (86.7) | 573 (91.7) | 73 (86.9) | ||||
| Present | 36 (8.0) | 27 (10.5) | 43 (8.2) | 20 (10.9) | 50 (8.2) | 13 (13.3) | 52 (8.3) | 11 (13.1) | ||||
| Death | 0.536 | 0.696 | 0.168 | 0.088 | ||||||||
| Survival | 421 (93.1) | 229 (89.1) | 488 (92.8) | 162 (88.5) | 566 (92.6) | 84 (85.7) | 579 (92.6) | 71 (84.5) | ||||
| Death | 31 (6.9) | 28 (10.9) | 38 (7.2) | 21 (11.5) | 45 (7.4) | 14 (14.3) | 46 (7.4) | 13 (15.5) | ||||
*p-value was corrected by the Bonferroni method.